38011-77-7

Basic information

• Product Name: 1-(3-bromopropyl)-2-methoxybenzene
• CAS NO: 38011-77-7
• Molecular Formula: C₁₀H₁₃BrO
• Molecular Weight: 229.1136
• Mol File: 38011-77-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 256.8°C at 760 mmHg
• Flash Point: 101.7°C
• Density: 1.302g/cm³
• Vapor Pressure: 0.0242mmHg at 25°C
• Refractive Index: 1.535
• CAS DataBase Reference: 1-(3-bromopropyl)-2-methoxybenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-bromopropyl)-2-methoxybenzene(38011-77-7)
• EPA Substance Registry System: 1-(3-bromopropyl)-2-methoxybenzene(38011-77-7)

Safety Data

• Hazardous Substances Data: 38011-77-7(Hazardous Substances Data)

Usage

General Description

1-(3-bromopropyl)-2-methoxybenzene, also known as 3-bromoallylanisole, is an organic compound with the chemical formula C10H13BrO. It is a colorless liquid with a molecular weight of 225.11 g/mol. This chemical is commonly used as a starting material in the synthesis of various pharmaceuticals and agrochemicals, as well as in the production of fragrances and flavorings. It is known for its strong and distinct odor, and it is classified as a hazardous substance due to its flammability and potential health hazards. Additionally, 1-(3-bromopropyl)-2-methoxybenzene is an important intermediate in organic synthesis and is used in the manufacturing of various specialty chemicals.

Upstream product

• 3698-28-0 2-allylanisole 
• 10493-37-5 3-(2-methoxyphenyl)propan-1-ol 
• 578-57-4 2-bromoanisole 
• 5469-66-9 propane-1,3-diol ditosylate 
• 109-64-8 1,3-dibromo-propane 
• 24393-54-2 ethyl 3-(2-methoxyphenyl)prop-2-enoate 
• 1011-54-7 2-methoxycinnamic acid 
• 6342-77-4 2-methoxy-benzenepropanoic acid 
• 135-02-4 ortho-anisaldehyde 

Downstream Products

• 101356-01-8 1-[3-(2-methoxy-phenyl)-propyl]-piperidine 
• 18655-51-1 2-(3-Aminopropyl)-1-methoxybenzene 
• 110662-49-2 bis-[3-(2-methoxy-phenyl)-propyl]-amine 
• 124778-33-2 1,1'-(1,3-propanediyl)bis[2-methoxybenzene] 
• 61440-44-6 p-[3-(o-Methoxyphenyl)propyl]aminobenzoic Acid 
• 1093172-48-5 [5-(2-{4-[3-(2-methoxyphenyl)propoxy]-3-trifluoromethylphenyl}ethyl)-2,2-dimethyl-1,3-dioxan-5-yl]carbamic acid t-butyl ester 
• 61440-43-5 ethyl p-[3-(o-methoxyphenyl)propyl]aminobenzoate 
• 101581-87-7 N-phenylmethyl-3-(2-methoxyphenyl)propylamine 
• 109475-06-1 [3-(2-methoxy-phenyl)-propyl]-[2]thienylmethyl-amine 
• 101104-93-2 furfuryl-[3-(2-methoxy-phenyl)-propyl]-amine 
• 152063-60-0 1,3-Bis<3-(3-bromopropyl)-2-methoxyphenyl>propane 
• 152063-59-7 1,3-Bis(3-bromo-2-methoxyphenyl)propane 
• 104179-18-2 3-Methylamino-1-<2-methoxy-phenyl>-propan 
• 77318-18-4 [3-(2-methoxy-phenyl)-propyl]-dimethyl-amine 

Relevant articles and documents

Compounds for and methods of treating diseases

The present invention provides heterocyclic compounds of formula (I) that modulate biological metals and to pharmaceutical compositions containing such compounds. The invention particularly relates to compounds that modulate iron and to compounds for the treatment of diseases, particularly neurological diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Alzheimer-type dementia, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and multiple system atrophy (MSA).

Inhibitors of microsomal triglyceride transfer protein and method

Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure STR1 wherein R1 to R7, Q, X and Y are as defined herein.

SUBSTITUTED 1H-IMIDAZOLES

Substituted 4-(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-imidazoles and 4-(2,3-dihydro-1H-inden-1-yl)-1H-imidazoles, their optical isomers and their racemic mixtures, their salts, methods for preparing them and therapeutic compositions containing them. These compounds have the general formula STR1 wherein n=1 or 2,R 1, R. sub.2, R 3 and R 4 =hydrogen, halogen, hydroxyl C 1-C 4 alkyl or C 1-C 4 alkoxy,R 5 = hydrogen of C 1-C 4 alkyl with the proviso that R 1, R. sub.2, R 3, R. sub.4 and R 5, cannot simultaneously be hydrogen when n is equal to 2. These new compounds exhibit anti-ischemic and anti-hypertensive activities.